TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24520744
Drug: Distal vein
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal vein patch modification
Study: 21160018
Drug: Arthroscopic rotator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopic rotator cuff repair without augmentation
Study: 19069461
Drug: alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-lipoic acid (600 mg/day)
Study: 19069461
Drug: mexidol (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: mexidol (300 mg/day)
Study: 16596054
Drug: Controlled hyperthyroidism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled hyperthyroidism on medical therapy (group B)
Study: 1442643
Drug: Formal hypnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formal hypnosis with different treatment strategies (groups one and two)
Study: 31751012
Drug: Comparator EGFR-TKIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator EGFR-TKIs (gefitinib at 250 mg once daily or erlotinib at 150 mg once daily)
Study: 29576358
Drug: PAS (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS (400 mg PS & 400 mg PA per day)
Study: 25682232
Drug: Tiotropium 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 5 μg
Study: 27578478
Drug: Placebo 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2.5 μg
Study: 17956932
Drug: Nurse-led treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led treatment (after 7 sessions)
Study: 8260372
Drug: Sequential ifosfamide/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential ifosfamide/carboplatin
Study: 18831897
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg twice daily)
Study: 2188774
Drug: Oxycodone hydrochloride
Normalized name: Oxycodone Hydrochloride
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride
Study: 27479098
Drug: Complicated Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated Grief Treatment (CGT)
Study: 24974864
Drug: Calcium Hydroxide
Normalized name: Calcium Hydroxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium Hydroxide preceded by Low Level Laser Therapy (LLLT + CH)
Study: 24067553
Drug: CYD-TDV (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD-TDV (3 doses at 0, 6, and 12 months)
Study: 11397724
Drug: 450 mL
Normalized name: ALCOHOL 270 mL in 450 mL EXTRACORPOREAL GEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mL of black tea initially, followed by 900 mL daily for 4 weeks
Study: 30034230
Drug: TIO+OLO 5/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIO+OLO 5/5 μg
Study: 27173787
Drug: PR therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR therapy
Study: 24836914
Drug: Reading and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading and language intervention (two 9-week blocks of daily intervention delivered by trained teaching assistants)
Study: 15807187
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy (2 microg oral Alfacalcidol twice or thrice weekly)
Study: 15807187
Drug: Daily therapy
Normalized name: Konsyl Daily Therapy Fiber Laxative 625mg Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily therapy (0.5 microg oral Alfacalcidol per day)
Study: 6358652
Drug: Pulse therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulse therapy
Study: 12211526
Drug: Autologous hematopoietic
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem cell transplantation (HSCT) following high-dose chemotherapy
Study: 10180718
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled from the piezoelectric device (PED)
Study: 10180718
Drug: Albuterol inhaled
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol inhaled from the metered dose inhaler (MDI)
Study: 30337921
Drug: HFA‐BDP metered‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐BDP metered‐dose inhaler (MDI) ETN (n = 11)
Study: 9467248
Drug: Intravenous load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous load of hypertonic glucose solution
Study: 19717844
Drug: Warfarin (adjusted-dose)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Warfarin (adjusted-dose)
Study: 23446086
Drug: Control solutions
Normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control solutions containing no diclofenac
Study: 16127039
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg administered intravenously
Study: 12122921
Drug: NK1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK1 receptor antagonists
Study: 8274583
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (Control)
Study: 2125794
Drug: Baseline (No
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (No infusion)
Study: 807094
Drug: Formula diets
Normalized name: CIDER VINEGAR DIET FORMULA CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula diets varying in protein and calorie content (100 or 175 kcal/kg and 1 or 4 g/kg)
Study: 807094
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of 100,000 IU water-miscible vitamin A palmitate
Study: 807094
Drug: Stabilization period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization period with fluids, antibiotics, and increasing intake of protein and calories to 1 g protein and 100 kcal/kg
Study: 31843425
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance during treatment
Study: 31034032
Drug: Clopidogrel plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel plus aspirin (600 mg loading dose on day 1 followed by 75 mg daily for days 2-90)
Study: 31034032
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (50 to 325 mg/d)
Study: 16763533
Drug: Iloprost (28-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloprost (28-day intravenous treatment)
Study: 28768785
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1000 mg intravenously
Study: 19634510
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (clopidogrel 75 mg)
Study: 19634510
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (clopidogrel 75 mg)
Study: 19634510
Drug: Test preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test preparation (CBS)
Study: 19634510
Drug: Reference preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference preparation (CBS)
Study: 16942589
Drug: Doxazosin GITS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin GITS 4 mg q.i.d.
Study: 16942589
Drug: Tamsulosin 0.4
Normalized name: tamsulosin 0.4 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.4 mg q.i.d.
Study: 11356438
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone followed by 400 mg oral misoprostol (home administration)
Study: 11356438
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone followed by 400 mg oral misoprostol (clinic administration)
Study: 8204244
Drug: 80 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms/kg of preservative‐free epidural morphine with 40 micrograms/kg of butorphanol
Study: 8204244
Drug: 80 micrograms/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 micrograms/kg of preservative‐free epidural morphine
Study: 14676074
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (500 mg)
Study: 22174811
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg per day of monomeric and oligomeric flavanols (MOF) from grape seeds
Study: 12775425
Drug: Topotecan treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topotecan treatment
Study: 26076387
Drug: I-gel (IG)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-gel (IG)
Study: 9521334
Drug: Abciximab therapy
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab therapy and low-dose, weight-adjusted heparin
Study: 9521334
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and standard-dose heparin
Study: 6897633
Drug: Continuous chlorambucil/prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous chlorambucil/prednisolone therapy (A)
Study: 6897633
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose prednimustine (B)
Study: 6897633
Drug: Intermittent high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent high-dose prednimustine (C)
Study: 27305192
Drug: Tenofovir disoproxil
Normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil fumarate (TDF) 300 mg per day from 30 to 32 weeks of gestation until postpartum week 4
Study: 27305192
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care without antiviral therapy
Study: 25216842
Drug: Fixed-dose combinations
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combinations (FDCs)
Study: 1901200
Drug: Separate drugs
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate drugs
Study: 15818697
Drug: Infliximab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (3 mg/kg or 10 mg/kg every 4 or 8 weeks) plus methotrexate (MTX)
Study: 9849280
Drug: Suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suxamethonium 1.0 mg.kg‐1
Study: 9849280
Drug: Rocuronium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocuronium 1.0 mg.kg‐1
Study: 7905719
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol (2 x 80 mg/day)
Study: 28966878
Drug: FTM ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FTM ratings and digitizing tablet
Study: 18063874
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antifungal prophylaxis)
Study: 18082206
Drug: 2.5% transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% transdermal dihydrotestosterone gel daily for 3 months (group 1)
Study: 15871014
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate preparation
Study: 14569404
Drug: Carob pulp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carob pulp preparation (15 g/d)
Study: 10389803
Drug: OND pretreatment
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OND pretreatment (4 mg in 2 mg/mL solution)
Study: 27562742
Drug: Integrase inhibitor
Normalized name: Integrase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase inhibitor regimen (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
Study: 27562742
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor based regimen
Study: 27562742
Drug: Integrase inhibitor
Normalized name: Integrase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrase inhibitor regimen
Study: 22580040
Drug: Scopoletin (equivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scopoletin (equivalent dose present in AFE)
Study: 8556173
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation therapy
Study: 7353472
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of methamphetamine
Study: 31594077
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with HBsAg < 3,000 IU/ml at 24 weeks of treatment.
Study: 27840148
Drug: Primary angioplasty
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary angioplasty with radial access, bivalirudin, thromboaspiration, drug-eluting stents
Study: 18024668
Drug: Blood transfusion
Normalized name: Blood transfusion, auxiliary products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood transfusion therapy
Study: 15619132
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution containing 300 mg flecainide and 20 mg cisapride
Study: 29477795
Drug: S-1 (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40, 50, or 60 mg twice daily for four of six weeks for up to four cycles)
Study: 29477795
Drug: gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine (1000 mg/m2 weekly for three of four weeks for up to six cycles)
Study: 27027929
Drug: Ivermectin 200 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin 200 μg/kg body weight single oral dose, repeated after one week.
Study: 27027929
Drug: Benzyl benzoate
Normalized name: Benzyl Benzoate
DrugBank: Benzyl benzoate (DB00676)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzyl benzoate 20% cream.
Study: 27027929
Drug: Permethrin 2.5%‐5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permethrin 2.5%‐5% lotion.
Study: 12756407
Drug: Hypertension risk
Normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertension risk factors measured including urbanisation, obesity, plasma fibrinogen, lipids, insulin, serum gamma glutamyl‐transferase, dietary intake, smoking and alcohol consumption.
Study: 10933123
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment plus antibiotics
Study: 8613045
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin injection into the lower esophageal sphincter
Study: 8613045
Drug: Second injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second injection of botulinum toxin
Study: 1350540
Drug: Prostaglandin gel
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin gel induction of labor
Study: 31450518
Drug: Home-based carer-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based carer-assisted therapy
Study: 31450518
Drug: Hospital-based therapist-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital-based therapist-delivered therapy
Study: 29730659
Drug: Intravenous levothyroxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous levothyroxine treatment
Study: 20854630
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 to 16 mg once daily for 7 days)
Study: 17967672
Drug: Conventional catheter
Normalized name: CATHETER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional catheter group 1 (CC 1)
Study: 11434650
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (ARG) 9.0 g/d for 9 days, then 18.0 g/d for 9 more days in HD patients
Study: 11434650
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (ARG) in crossover study
Study: 11434650
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (ARG)
Study: 11434650
Drug: Oral arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral arginine (ARG) (+/- CanO)
Study: 4856938
Drug: 0.5% etidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% etidocaine for bilateral intercostal nerve block (plain solution)
Study: 30059196
Drug: ALKS 3831
Normalized name: ALKS 29
DrugBank: ALKS 29 (DB05723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALKS 3831 (10 mg OLZ/10 mg SAM)
Study: 30059196
Drug: OLZ (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLZ (10 mg OLZ)
Study: 30059196
Drug: B-OLZ (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: B-OLZ (10 mg B-OLZ)
Study: 28627861
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dry land therapy, N=15 patients)
Study: 21334498
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) intervention on PDAs for 4 weeks
Study: 14732659
Drug: 20% wt/vol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% wt/vol aminolevulinic acid hydrochloride (ALA) followed by photodynamic therapy (PDT)
Study: 7923645
Drug: Heparin (5000-U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000-U bolus and 1000-1300-U/h infusion, adjusted to APTT of 60 to 90 seconds)
Study: 7923645
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with Hirudin
Study: 7923645
Drug: Both thrombin
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both thrombin inhibitors
Study: 2468874
Drug: Nitrendipine 10
Normalized name: nitrendipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 10 mg b.i.d.
Study: 2468874
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg q.d.
Study: 2468874
Drug: Nitrendipine 5‐20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine 5‐20 mg b.i.d.
Study: 2468874
Drug: Propranolol 40‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40‐120 mg b.i.d.
Study: 23650884
Drug: Grammar treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grammar treatment (experimental group)
Study: 23650884
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (control group)
Study: 15138095
Drug: High lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lactate group (lactate > 2 mmol/L)
Study: 11052960
Drug: Hypoglycemia of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia of 60 mg/dl
Study: 11052960
Drug: Hypoglycemia of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemia of 60 and 50 mg/dl
Study: 8259037
Drug: Recombinant alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha‐2b interferon at 3 MU three times weekly for 3 months, increased to 6 MU for non-responders for an additional 3 months
Study: 8259037
Drug: Increased dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dosage of interferon to 6 MU for non-responders
Study: 3936739
Drug: buccal nitroglycerin
Normalized name: nitroglycerin Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: buccal nitroglycerin
Study: 12870776
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (9 g)
Study: 3619386
Drug: Urokinase (UK)
DrugBank: Urokinase (DB00013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urokinase (UK) with heparin (5,000 U IV bolus, followed by 150,000 IU UK IV bolus, then 12,000 IU UK/min for 90 min, total dose 1,230,000 IU)
Study: 3619386
Drug: Heparin alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin alone (5,000 U IV bolus)
Study: 9586605
Drug: Intravenous anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anesthesia
Study: 28252528
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg daily
Study: 26780276
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg) daily for three months
Study: 24106334
Drug: Clonidine 25
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 25 µg
Study: 24106334
Drug: Clonidine 150
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine 150 µg
Study: 25231091
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg peramivir
Study: 15017503
Drug: 0.05 mg
Normalized name: biotin 0.05 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg clonidine twice a day
Study: 15017503
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg clonidine twice a day
Study: 15017503
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg clonidine twice a day
Study: 10706232
Drug: Daily vitamin‐mineral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vitamin‐mineral supplementation at 50% of the U.S. daily recommended allowance (RDA) for 3 months
Study: 8230075
Drug: Salt-sugar solution
Normalized name: SUGAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-sugar solution preparation by mothers
Study: 8737885
Drug: 25% emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% emulsion of oil of bitter orange (OBO) three times daily
Study: 8737885
Drug: 20% OBO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% OBO in alcohol three times daily
Study: 8737885
Drug: Pure OBO,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pure OBO, once daily
Study: 1389848
Drug: Indomethacin 100
Normalized name: indomethacin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 100 mg i.v. before surgery, followed by 100 mg rectally 6 and 12 h after surgery and at 08:00, 16:00 and 23:00 on the next day